Alzheimer’s disease (AD) and Parkinson’s disease (PD), represent major global public health challenges. Yet, 30-50% with AD or PD is believed to go undiagnosed. Early diagnosis is beneficial for patients and carers and can result in substantial cost savings to healthcare systems. Current diagnostic measures are unscalable, expensive and time-consuming and thus have limited accessibility as frontline diagnostic tools. In collaboration with EDoN (a UK led global initiative on Early Detection of Neurodegenerative diseases, see www.edon-initiative.org). PANDA will address these needs and develop and assess a wearable solution that can measure and analyse subtle changes in sleep and autonomic function, instrumental for precision medicine and early biomarkers of neurodegeneration, thus moving from current reactive diagnostic options to early detection, protection and prevention. PANDA further addresses the need for cost-effectiveness, timeliness, and capacity in healthcare systems, offering unattended home monitoring as an alternative to the classic interaction between patient and health care system. Thus, PANDA addresses operational limitations, while moving the state-of-the-art for frontline and early diagnostics. Our commercial goal is to provide a solution for new intervention targets for future clinical studies and enable precision medicine at scale towards an unobtrusive and cost-efficient diagnostics of neurodegenerative diseases.